Reginald Seeto - Caredx President Chief Business Officer
| CDNA Stock | USD 19.32 0.42 2.22% |
President
Dr. Reginald Seeto, MBBS., is President, Chief Business Officer of the Company. Dr. Seeto served as the Chief Operating Officer of Ardelyx, Inc., a specialized biopharmaceutical company, from October 2016 through midAugust 2018 and continued with Ardelyx, Inc. from August 2018 through December 2018 as a consultant. From April 2008 until October 2016, Dr. Seeto held various positions of increasing responsibility at MedImmune Limited, a biotechnology company and subsidiary of AstraZeneca Plc, and at AstraZeneca, most recently serving as vice president, head of partnering and strategy for AstraZeneca. Earlier, he served as company president of AstraZeneca Thailand and before that, as executive vice president of corporate development and strategy for MedImmune. Prior to joining AstraZenecaMedImmune, Dr. Seeto held senior marketing roles at Organon Biosciences, which was acquired by Schering Plough in 2007, and Boehringer Ingelheim Pharmaceuticals. Earlier, Dr. Seeto served as an engagement manager for McKinsey Company and started his career as a practicing medical doctor and clinical researcher in Australia since 2018.
| Age | 52 |
| Tenure | 7 years |
| Address | 8000 Marina Boulevard, South San Francisco, CA, United States, 94005 |
| Phone | 415 287 2300 |
| Web | https://caredx.com |
Caredx Management Efficiency
The company has return on total asset (ROA) of (0.0701) % which means that it has lost $0.0701 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1643 %, meaning that it created $0.1643 on every $100 dollars invested by stockholders. Caredx's management efficiency ratios could be used to measure how well Caredx manages its routine affairs as well as how well it operates its assets and liabilities. At present, Caredx's Return On Tangible Assets are projected to increase slightly based on the last few years of reporting. The current year's Return On Capital Employed is expected to grow to 0.11, whereas Return On Equity is forecasted to decline to 0.13. At present, Caredx's Non Currrent Assets Other are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 369.4 M, whereas Total Assets are forecasted to decline to about 255.1 M.Similar Executives
| Found 14 records | PRESIDENT Age | ||
| Olivier Jarry | DarioHealth Corp | 63 | |
| David Smith | Charles River Laboratories | 58 | |
| Patrick Finn | Twist Bioscience Corp | 53 | |
| Joseph LaPlume | Charles River Laboratories | 50 | |
| Charles Dadswell | Illumina | 65 | |
| Paula Green | Twist Bioscience Corp | 57 | |
| William Barbo | Charles River Laboratories | 64 | |
| Solomon MBA | Natera Inc | 42 | |
| John Fesko | Natera Inc | 46 | |
| Toby Juvenal | Castle Biosciences | 63 | |
| Birgit Girshick | Charles River Laboratories | 55 | |
| AmirAli Talasaz | Guardant Health | 46 | |
| Mark Verratti | Myriad Genetics | 57 | |
| Michael Knell | Charles River Laboratories | 48 | |
Management Performance
| Return On Equity | 0.16 | ||||
| Return On Asset | -0.0701 |
Caredx Inc Leadership Team
Elected by the shareholders, the Caredx's board of directors comprises two types of representatives: Caredx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Caredx. The board's role is to monitor Caredx's management team and ensure that shareholders' interests are well served. Caredx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Caredx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Marco Scheller, Senior Operations | ||
| Ian Cooney, Vice Relations | ||
| Jessica Meng, Chief Officer | ||
| Jeffrey Novack, General Secretary | ||
| Hal Gibson, Senior Planning | ||
| GS Jha, Chief VP | ||
| Reginald Seeto, President Chief Business Officer | ||
| Sasha MBA, Ex Officer | ||
| Abhishek Jain, CFO Officer | ||
| Mickey MD, Sr Product | ||
| Peter Maag, CEO and President and Director | ||
| Abraham Esq, Chief Counsel | ||
| Kashif Rathore, Head Engineering | ||
| Stacey Follon, Senior Resources | ||
| Alexander Johnson, President Services | ||
| Jing Huang, Chief Officer | ||
| Marcel Konrad, Sr Accounting | ||
| CPA CFA, Chief Officer | ||
| Marica Grskovic, Chief Officer | ||
| Robert Woodward, Chief Officer | ||
| John Hanna, CEO President |
Caredx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Caredx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | ||||
| Return On Asset | -0.0701 | ||||
| Profit Margin | 0.16 % | ||||
| Operating Margin | (0.23) % | ||||
| Current Valuation | 830.23 M | ||||
| Shares Outstanding | 55.43 M | ||||
| Shares Owned By Insiders | 3.37 % | ||||
| Shares Owned By Institutions | 94.90 % | ||||
| Number Of Shares Shorted | 4.78 M | ||||
| Price To Earning | (4.25) X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Caredx Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Caredx's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Caredx Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Caredx Inc Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Caredx Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Caredx. If investors know Caredx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Caredx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.93 | Revenue Per Share | Quarterly Revenue Growth 0.32 | Return On Assets | Return On Equity |
The market value of Caredx Inc is measured differently than its book value, which is the value of Caredx that is recorded on the company's balance sheet. Investors also form their own opinion of Caredx's value that differs from its market value or its book value, called intrinsic value, which is Caredx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Caredx's market value can be influenced by many factors that don't directly affect Caredx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Caredx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Caredx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Caredx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.